# A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

> **NCT03890666** · PHASE4 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 333 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Albuterol eMDPI DS
- **DRUG:** albuterol

## Key facts

- **NCT ID:** NCT03890666
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-04
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890666, "A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03890666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*